Filing Flows › Impact Biomedical (IBO) › R&D spending
Impact Biomedical (IBO) R&D spending by quarter
Impact Biomedical's R&D spending was $76K in Q2 2026 (second quarter 2026), +65% from Q1 2026. Over the last 5 quarters it ranged from $46K (Q1 2026) to $110K (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $76K | +65% | +1% |
| Q1 2026 | $46K | -58% | — |
| Q4 2025 | $110K | +112% | — |
| Q3 2025 | $52K | -31% | — |
| Q2 2025 | $75K | — | — |
Q2 2026 at a glance
Impact Biomedical, Q2 2026: revenue $3K (-57% year over year), net loss $700K, operating cash flow $470K. The chart follows the revenue to costs, profit and cash.
Questions
What is Impact Biomedical's R&D spending?
Impact Biomedical's R&D spending was $76K in Q2 2026 (second quarter 2026), +65% from Q1 2026.
How has Impact Biomedical's R&D spending changed?
Over the last 5 quarters it ranged from $46K (Q1 2026) to $110K (Q4 2025).